The Online Investor
Elan Corp Plc (ELN)

Elan Corp is a neuroscience-based biotechnology company headquartered in Ireland. Co.'s business is organized into two business units: BioNeurology and Elan Drug Technologies (EDT). Co.'s BioNeurology business unit engages in research, development and commercial activities primarily in the areas of Alzheimer's disease, Parkinson's disease, MS, Crohn's disease and severe chronic pain. Co. has a range of products at various stages of development in relation to each of these therapeutic areas. EDT develops and manufactures pharmaceutical products that deliver clinical benefits to patients, using its proprietary drug technologies in collaboration with pharmaceutical companies.
Company Name: 
Elan Corp Plc
Website: 
www.elan.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree ELN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Elan Corp Plc (ELN) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.